A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

NCT01425996 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Lipotecan® (TLC388)

Sponsor

Taiwan Liposome Company